NanoViricides Ownership
| NNVC Stock | USD 1.68 0.04 2.44% |
Shares in Circulation | First Issued 2005-09-30 | Previous Quarter 14.6 M | Current Value 16 M | Avarage Shares Outstanding 4.8 M | Quarterly Volatility 4.2 M |
NanoViricides | Build AI portfolio with NanoViricides Stock |
NanoViricides Stock Ownership Analysis
The book value of the company was now reported as 0.55. The company recorded a loss per share of 0.69. NanoViricides last dividend was issued on the 24th of September 2019. The entity had 1:20 split on the 24th of September 2019. NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company was founded in 2005 and is based in Shelton, Connecticut. Nanoviricides operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 17 people. To find out more about NanoViricides contact the company at 203 937 6137 or learn more at https://www.nanoviricides.com.Besides selling stocks to institutional investors, NanoViricides also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different NanoViricides' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align NanoViricides' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
NanoViricides Quarterly Liabilities And Stockholders Equity |
|
Roughly 4.0% of NanoViricides are currently held by insiders. Unlike NanoViricides' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against NanoViricides' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of NanoViricides' insider trades
NanoViricides Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NanoViricides insiders, such as employees or executives, is commonly permitted as long as it does not rely on NanoViricides' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NanoViricides insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NanoViricides Outstanding Bonds
NanoViricides issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NanoViricides uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NanoViricides bonds can be classified according to their maturity, which is the date when NanoViricides has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NanoViricides offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NanoViricides' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nanoviricides Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nanoviricides Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NanoViricides. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NanoViricides. If investors know NanoViricides will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NanoViricides listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NanoViricides is measured differently than its book value, which is the value of NanoViricides that is recorded on the company's balance sheet. Investors also form their own opinion of NanoViricides' value that differs from its market value or its book value, called intrinsic value, which is NanoViricides' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NanoViricides' market value can be influenced by many factors that don't directly affect NanoViricides' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NanoViricides' value and its price as these two are different measures arrived at by different means. Investors typically determine if NanoViricides is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NanoViricides' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.